Peringatan Keamanan

LD50/LC50:
Draize test, rabbit, eye: 100 mg/24H Moderate; Oral,
mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat:
LD50 = 980 mg/kg.

Ceftaroline fosamil

DB06590

small molecule approved investigational

Deskripsi

Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria:
Acute bacterial skin and skin structure infections.
Community-acquired bacterial pneumonia.

Struktur Molekul 2D

Berat 684.67
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1.60 hours (600 mg dose).
Volume Distribusi Median 20.3 L (18.3-21.6 L).
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Ceftaroline fosamil is converted into bioactive ceftaroline in plasma by a phosphatase enzyme. Hydrolysis of the beta-lactam ring of ceftaroline occurs to form the microbiologically inactive, open-ring metabolite ceftaroline M-1.

Rute Eliminasi

primarily eliminated by the kidneys (6% in feces within 48 hours).

Interaksi Obat

795 Data
Probenecid The serum concentration of Ceftaroline fosamil can be increased when it is combined with Probenecid.
Foscarnet The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ceftaroline fosamil.
Tenofovir disoproxil Ceftaroline fosamil may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Ceftaroline fosamil may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Ceftaroline fosamil may increase the nephrotoxic activities of Tenofovir.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftaroline fosamil.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Ceftaroline fosamil.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Ceftaroline fosamil.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftaroline fosamil.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Ceftaroline fosamil.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Ceftaroline fosamil.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Ceftaroline fosamil.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Ceftaroline fosamil.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Ceftaroline fosamil.
Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Ceftaroline fosamil.
Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Ceftaroline fosamil.
Nabumetone The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Ceftaroline fosamil.
Ketorolac The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Ceftaroline fosamil.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Ceftaroline fosamil.
Celecoxib The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Ceftaroline fosamil.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ceftaroline fosamil.
Tolmetin The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Ceftaroline fosamil.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Ceftaroline fosamil.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Ceftaroline fosamil.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Ceftaroline fosamil.
Diclofenac The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Ceftaroline fosamil.
Sulindac The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Ceftaroline fosamil.
Bacitracin The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Ceftaroline fosamil.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceftaroline fosamil.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Ceftaroline fosamil.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Ceftaroline fosamil.
Pentamidine The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Ceftaroline fosamil.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Ceftaroline fosamil.
Naproxen The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Ceftaroline fosamil.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Ceftaroline fosamil.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Ceftaroline fosamil.
Meloxicam The risk or severity of methemoglobinemia can be increased when Ceftaroline fosamil is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Ceftaroline fosamil.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Ceftaroline fosamil.
Etacrynic acid The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Ceftaroline fosamil.
Ceforanide The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Ceftaroline fosamil.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Ceftaroline fosamil.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Ceftaroline fosamil.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Ceftaroline fosamil.
Balsalazide The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Ceftaroline fosamil.
Cefditoren The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Ceftaroline fosamil.
Atazanavir The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Ceftaroline fosamil.
Colistimethate The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Ceftaroline fosamil.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Ceftaroline fosamil.
Cefapirin The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Ceftaroline fosamil.
Cefprozil The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Ceftaroline fosamil.
Olsalazine The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Olsalazine.
Lumiracoxib The risk or severity of nephrotoxicity can be increased when Lumiracoxib is combined with Ceftaroline fosamil.
Cefamandole The risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Ceftaroline fosamil.
Cefazolin The risk or severity of nephrotoxicity can be increased when Cefazolin is combined with Ceftaroline fosamil.
Cefonicid The risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Ceftaroline fosamil.
Cefoperazone The risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Ceftaroline fosamil.
Cefoxitin The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Ceftaroline fosamil.
Ceftizoxime The risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Ceftaroline fosamil.
Magnesium salicylate The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Ceftaroline fosamil.
Salsalate The risk or severity of nephrotoxicity can be increased when Salsalate is combined with Ceftaroline fosamil.
Choline magnesium trisalicylate The risk or severity of nephrotoxicity can be increased when Choline magnesium trisalicylate is combined with Ceftaroline fosamil.
Cefepime The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Ceftaroline fosamil.
Cefacetrile The risk or severity of nephrotoxicity can be increased when Cefacetrile is combined with Ceftaroline fosamil.
Cefpodoxime The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Ceftaroline fosamil.
Antrafenine The risk or severity of nephrotoxicity can be increased when Antrafenine is combined with Ceftaroline fosamil.
Aminophenazone The risk or severity of nephrotoxicity can be increased when Aminophenazone is combined with Ceftaroline fosamil.
Antipyrine The risk or severity of nephrotoxicity can be increased when Antipyrine is combined with Ceftaroline fosamil.
Tiaprofenic acid The risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Ceftaroline fosamil.
Lopinavir The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Ceftaroline fosamil.
Etoricoxib The risk or severity of nephrotoxicity can be increased when Etoricoxib is combined with Ceftaroline fosamil.
Hydrolyzed Cephalothin The risk or severity of nephrotoxicity can be increased when Hydrolyzed Cephalothin is combined with Ceftaroline fosamil.
Cephalothin Group The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Ceftaroline fosamil.
Oxyphenbutazone The risk or severity of nephrotoxicity can be increased when Oxyphenbutazone is combined with Ceftaroline fosamil.
Latamoxef The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Ceftaroline fosamil.
Nimesulide The risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Ceftaroline fosamil.
Benoxaprofen The risk or severity of nephrotoxicity can be increased when Benoxaprofen is combined with Ceftaroline fosamil.
Metamizole The risk or severity of nephrotoxicity can be increased when Metamizole is combined with Ceftaroline fosamil.
Zomepirac The risk or severity of nephrotoxicity can be increased when Zomepirac is combined with Ceftaroline fosamil.
Ceftobiprole The risk or severity of nephrotoxicity can be increased when Ceftobiprole is combined with Ceftaroline fosamil.
Cimicoxib The risk or severity of nephrotoxicity can be increased when Cimicoxib is combined with Ceftaroline fosamil.
Lornoxicam The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Lornoxicam.
Zaltoprofen The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Zaltoprofen.
Azapropazone The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Azapropazone.
Parecoxib The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Parecoxib.
Salicylamide The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Salicylamide.
Kebuzone The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Kebuzone.
Isoxicam The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Isoxicam.
Indoprofen The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Indoprofen.
Ibuproxam The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Ibuproxam.
Floctafenine The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Floctafenine.
Fenbufen The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Fenbufen.
Etofenamate The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Etofenamate.
Epirizole The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Epirizole.
Cefaloridine The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Cefaloridine.
Cefminox The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Cefminox.
Dexibuprofen The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Dexibuprofen.
Droxicam The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Droxicam.
Tolfenamic acid The risk or severity of nephrotoxicity can be increased when Ceftaroline fosamil is combined with Tolfenamic acid.

Target Protein

Penicillin-binding protein dacA

Referensi & Sumber

Synthesis reference: http://www.google.com/patents/US20110071114
Artikel (PubMed)
  • PMID: 20334458
    Steed ME, Rybak MJ: Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy. 2010 Apr;30(4):375-89. doi: 10.1592/phco.30.4.375.
  • PMID: 20001879
    Kollef MH: New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc. 2009 Dec;11(4):282-6.
  • PMID: 19207097
    Kanafani ZA, Corey GR: Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future Microbiol. 2009 Feb;4(1):25-33. doi: 10.2217/17460913.4.1.25.
  • PMID: 18246523
    Parish D, Scheinfeld N: Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs. 2008 Feb;9(2):201-9.
  • PMID: 23459495
    MacGowan AP, Noel AR, Tomaselli S, Bowker KE: Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6. doi: 10.1128/AAC.01386-12. Epub 2013 Mar 4.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Teflaro
    Powder, for solution • 400 mg/20mL • Intravenous • US • Approved
  • Teflaro
    Powder, for solution • 600 mg/20mL • Intravenous • US • Approved
  • Zinforo
    Injection, powder, for solution • 600 mg • Intravenous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul